EI
KERX

EAM Investors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

EAM Investors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-214,898
Closed -$1.53M – 387
2017
Q3 		$1.53M Buy
+214,898
New +$1.55M 0.2% 226
2014
Q3 		– Sell
-168,513
Closed -$2.59M – 388
2014
Q2 		$2.59M Sell
168,513
-62,271
-27% -$883K 0.49% 34
2014
Q1 		$3.93M Sell
230,784
-12,131
-5% -$183K 0.71% 11
2013
Q4 		$3.15M Buy
242,915
+11,016
+5% +$132K 0.56% 26
2013
Q3 		$2.34M Sell
231,899
-11,230
-5% -$99.9K 0.47% 52
2013
Q2 		$1.82M Buy
+243,129
New +$1.9M 0.39% 67

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EAM Investors's KERX Position: Q4 2017 in Review

EAM Investors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 214,898 shares — an estimated $1.53M sold.

EAM Investors first reported a position in KERX in Q2 2013 and held it in 6 quarters. The position peaked at $3.93M in Q1 2014. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • EAM Investors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • EAM Investors sold 214,898 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $1.53M.
  • EAM Investors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 6 quarters.
  • EAM Investors's Keryx Biopharmaceuticals Inc position peaked at $3.93M in Q1 2014.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.